Abstract
BackgroundThis study was carried out to evaluate the prognostic value of KIBRA in breast cancer.MethodsThis retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features.ResultsA total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA–low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model.ConclusionOverall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy.
Highlights
This study was carried out to evaluate the prognostic value of KIBRA in breast cancer
We found that the Ki67 which is a proliferation marker, is expressed over 14% of cells in a breast cancer, mostly in the KIBRA positive than KIBRA-low breast cancers which is in keeping with the suggested optimal stimulation of growth of breast cancer cells by KIBRA
Our findings show that KIBRA is a biomarker which can be assessed routinely by IHC on breast cancer tissue of patients who are recommended for endocrine therapy
Summary
This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. The routinely used biomarkers of breast cancer are estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2). They are used in defining prognosis and identifying breast cancer patients for targeted therapy for decades; in the case of ER, for more than four decades [1]. Since KIBRA is found to be expressed both in the cytoplasm and the nucleus [3] it is important to identify which cellular component to be assessed in an IHC stained slide in order to make a clinically valid assessment of the KIBRA expression status. We assessed the correlation between survival and KIBRA expression in the two cellular components
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.